Story Stocks^®

Medtronic (MDT) is trading higher after delivering a solid fiscal Q4 beat and pairing it with a stronger-than-expected FY27 growth outlook, even though full-year EPS guidance of $5.90-6.00 came in below the $6.05 consensus. Q4 adjusted EPS of $1.55 and revenue of $9.81 bln both topped FactSet consensus expectations, while management guided for 6.75-7.25% organic revenue growth in FY27, supported by scaling platforms in cardiac ablation, renal denervation, robotics, and other newer businesses. However, earnings guidance still embeds tariff pressure, M&A dilution, the planned MiniMed separation, and calendar complexity from the extra week, which keeps the EPS outlook more conservative than the top-line outlook.

• Cardiac ablation: Cardiac Ablation Solutions remained the standout growth engine, up 78% worldwide in Q4 and 124% in the U.S., with the business on track to reach $2 bln in trailing revenue in 1Q27 as Affera adoption broadens.
• Margins: Adjusted gross margin improved to 65.4%, up 30 bps yr/yr, despite an 80-bps tariff hit worth $74 mln. Pricing and cost-down more than offset inflation. However, adjusted operating margin fell 230 bps to 25.5%, reflecting tariff pressure and a MiniMed-related payment, highlighting the near-term earnings headwinds embedded in FY27 guidance.
• Portfolio depth: Growth was not limited to one franchise, with Cardiovascular up 10.1% organic, Medical Surgical up 5.1%, Acute Care & Monitoring up low double digits, Endoscopy up high single digits, and Diabetes up 15% reported or 8.1% organic. Neuroscience was comparatively softer at 3% organic growth.
• Pipeline/commercial milestones: MDT added same-day support for the growth story with Hugo robotic surgery filings for U.S. general and gynecologic indications and new ICE investments to expand the Affera electrophysiology ecosystem.
• What to watch: Structural Heart was flat and U.S. TAVR remained soft, though management said weekly U.S. procedure volumes have stabilized over the last 8-10 weeks. Investors will also need to track whether MedSurg growth normalizes, how quickly tariff headwinds fade in the second half, and the timing and structure of the planned MiniMed separation, which FY27 guidance assumes remains consolidated throughout the year.

Briefing.com Analyst Insight

What changed today is less the quarter itself than the credibility of MDT's next phase. Management is now talking about CAS, Symplicity, Hugo, and Altaviva as active contributors rather than future options, and the FY27 organic growth guide suggests that broader portfolio acceleration is taking hold. Investors care because the stock had been under pressure and the market needed evidence that MDT could sustain above-historical growth while still expanding margins through portfolio change and operating leverage. The tension is that EPS guidance remains a bit shy of consensus, so the market still needs proof that tariff pressure, mix drag, and separation-related complexity will not dilute the benefit of stronger revenue growth. Sentiment should improve further if CAS continues to outgrow its market, Structural Heart stabilization holds, and second-half margin improvement materializes as tariffs are lapped. Sentiment would weaken if the current growth strength proves too concentrated in a few newer platforms or if the conservative guidance framework turns out to reflect more than just prudence.